GHTM

Global Health and Tropical Medicine

  • GHTM
    • Vision
    • Mission
    • Governance
    • Scientific Advisory Board
  • News
    • Outreach
    • Events
      • GHTM Sessions
      • Workshops
    • Articles
    • Jobs
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases and pathogens
      • IHC – Individual health care
    • Research in numbers
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases and pathogens
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Technical / administrative support
  • Publications
  • Education
    • Master Theses
    • PhD Theses
  • Services
Home / Archives for Journal of Antimicrobial Chemotherapy

From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: The stepwise mode of resistance acquisition

  • Autores: Couto I, Jordao L, Macedo R, Machado D, Perdigão J, Portugal I, Silva C, Viveiros M
  • Ano de Publicação: 2013
  • Journal: Journal of Antimicrobial Chemotherapy
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23054995

The development and transmission of extensively drug-resistant (XDR) tuberculosis (TB) constitutes a serious threat to the effective control of TB in several countries. Here, in an attempt to further elucidate the dynamics of the acquisition of resistance to second-line drugs and investigate an eventual role for eis promoter mutations in aminoglycoside resistance, we have studied a set of multidrug-resistant (MDR)/XDR-TB isolates circulating in Lisbon, Portugal.
Ler mais

HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.

  • Autores: Camacho RJ, Covens K, Palma AC, Snoeck J, Van Laethem K, Vandamme AM
  • Journal: Journal of Antimicrobial Chemotherapy
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=HIV-1+protease+mutation+82M+contributes+to+phenotypic+resistance+to+protease+inhibitors+in+subtype+G

OBJECTIVES:
The purpose of this study was the qualitative and quantitative assessment of the in vitro effect of HIV-1 protease (PR) mutation 82M on replication capacity and susceptibility to the eight clinically available PR inhibitors (PIs).
Ler mais

High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations

  • Autores: Boettger EC, Couto I, Machado D, Perdigão J, Portugal I, Ramos J, Ritter C, Viveiros M
  • Journal: Journal of Antimicrobial Chemotherapy
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23539241

The purpose of this study was to determine the levels of isoniazid and ethionamide resistance and to identify associated mutations in endemic multidrug-resistant (MDR) strains of Mycobacterium tuberculosis from the Lisbon metropolitan area, Portugal.
Ler mais

Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients

  • Autores: Alanio A, Bretagne S, Cesaro S, Cordonnier C, Donnelly JP, Einsele H, Hauser PM, Helweg-Larsen J, Lagrou K, Maertens J; Fifth European Conference on Infections in Leukemia (ECIL-5), Maschmeyer G, Matos O, Melchers WJ, The European Organization for Research and Treatment of Cancer (EORTC), the European LeukemiaNet (ELN), the Immunocompromised Host Society (ICHS)
  • Journal: Journal of Antimicrobial Chemotherapy
  • Link: https://www.ncbi.nlm.nih.gov/pubmed/27550990

Pneumocystis jirovecii can cause life-threatening pneumonia following treatment for haematological malignancies or after HSCT. The mortality rate of P. jirovecii pneumonia (PCP) in these patients is 30%-60%, especially after HSCT. The clinical presentation of PCP in haematology differs from that associated with HIV infection, with the disease being acute and more often severe, having a lower fungal burden and being more frequently linked to treatment with corticosteroids.
Ler mais

Mutations selected in HIV-2-infected patients failing a regimen including atazanavir

  • Autores: Aleixo MJ, Camacho RJ, Cavaco-Silva J, Cunha C, Faria D, Gomes P, Goncalves MF, Valadas E, Van Laethem K, Vandamme AM
  • Journal: Journal of Antimicrobial Chemotherapy
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/22977160

To investigate mutations selected in viruses from HIV-2-infected patients failing a highly active antiretroviral treatment (HAART) regimen including atazanavir/ritonavir.
Ler mais

  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »

About GHTM

GHTM is a R&D Center that brings together researchers from IHMT with a track record in Tropical Medicine and International/Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal
+351 213 652 600
+351 213 632 105

  • Facebook
  • YouTube

Subscribe Newsletter

  • How to get to GHTM/IHMT
  • GHTM Sessions
  • Research Groups
  • Cross-cutting issues
© Copyright 2023 IHMT-UNL Todos os Direitos Reservados.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    Project UID/Multi/04413/2013